Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13039200 | 0.86 | MEN1 (0.41) | MEN1KMT2AALDH1A1PKMGAA | |
| SCHEMBL13888874 | 0.85 | MEN1 (0.51) | MEN1KMT2AALDH1A1PKMGAA | |
| SCHEMBL2567226 | 0.84 | MEN1 (0.42) | MEN1KMT2AALDH1A1PKMGAA | |
| SCHEMBL17158265 | 0.81 | KMT2A (0.48) | MEN1KMT2AALDH1A1PKMGAA | |
| SCHEMBL17158194 | 0.80 | KMT2A (0.48) | MEN1KMT2AALDH1A1PKMGAA | |
| SCHEMBL2572031 | 0.80 | KMT2A (0.45) | MEN1KMT2AALDH1A1PKMGAA | |
| SCHEMBL5971181 | 0.77 | KMT2A (0.45) | MEN1KMT2AALDH1A1PKMGAA | |
| SCHEMBL13888780 | 0.76 | KMT2A (0.44) | MEN1KMT2AALDH1A1PKMGAA | |
| SCHEMBL4101227 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1GAATSHR | |
| SCHEMBL8193080 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1PKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078022-B1 | SPIRO BENZAZEPINES USED AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-09 | — | — | EP | disclosed |
| EP-2078022-B1 | SPIRO BENZAZEPINES USED AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-09 | — | — | EP | disclosed |
| US-7825110-B2 | Substituted spiroheterocycles | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825111-B2 | Substituted spiroheterocycles | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825111-B2 | Substituted spiroheterocycles | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825110-B2 | Substituted spiroheterocycles | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | DENG XIAOHU | 2009-04-23 | — | — | US | disclosed |
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | DENG XIAOHU | 2009-04-23 | — | — | US | disclosed |
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | DENG XIAOHU | 2009-04-23 | — | — | US | disclosed |
| WO-2008036759-A1 | SPIRO BENZAZEPINES AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036755-A1 | SPIRO BENZAZEPINES USED AS VASOPRESSIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | WO | disclosed |
| US-20080076753-A1 | SUBSTITUTED SPIROHETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076753-A1 | SUBSTITUTED SPIROHETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076754-A1 | SUBSTITUTED SPIROHETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076754-A1 | SUBSTITUTED SPIROHETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-27 | — | — | US | disclosed |
| EP-1633721-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005000819-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-23 | — | — | US | disclosed |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-23 | — | — | US | disclosed |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | REN, AVPR1B, WNK1 | MEN1 2498/4885KMT2A 2724/4885ALDH1A1 1177/4885 |
| US-20080076754-A1 | SUBSTITUTED SPIROHETEROCYCLES | AVPR2, AVPR1B, AVPR1A | MEN1 3209/4885KMT2A 4670/4885ALDH1A1 2156/4885 |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | REN, AVPR1B, WNK1 | MEN1 2498/4885KMT2A 2724/4885ALDH1A1 1177/4885 |
| US-20080076753-A1 | SUBSTITUTED SPIROHETEROCYCLES | AVPR2, AVPR1B, AVPR1A | MEN1 3251/4885KMT2A 4641/4885ALDH1A1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.